What is the starting dose of Strattera (atomoxetine) for an adult?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Starting Dose of Strattera (Atomoxetine) for Adults

For adults, Strattera should be initiated at 40 mg once daily, then increased after a minimum of 3 days to a target dose of 80 mg daily, administered either as a single morning dose or divided into morning and late afternoon/evening doses. 1

Initial Dosing Protocol

  • Start at 40 mg daily for all adults and adolescents weighing over 70 kg 1
  • Maintain this initial dose for at least 3 days before any increase 1
  • The 40 mg can be taken as a single dose or split into two divided doses (morning and late afternoon/evening) 1

Titration Schedule

  • After 3 days minimum, increase to the target dose of 80 mg daily 1
  • If optimal response is not achieved after 2-4 additional weeks at 80 mg, may increase to maximum of 100 mg daily 1
  • Maximum recommended dose is 100 mg/day for adults 1
  • No data support increased effectiveness at doses higher than 100 mg 1

Important Timing Considerations

  • Full therapeutic effect requires 6-12 weeks, unlike stimulants which work within hours 2
  • Set appropriate patient expectations about this delayed response timeline 2
  • Slow titration (increasing dose gradually at 1-2 week intervals) is generally better tolerated and helps avoid exceeding the optimal dose 2

Special Dosing Adjustments

For CYP2D6 Poor Metabolizers or Strong CYP2D6 Inhibitor Use

  • Start at 40 mg/day 1
  • Only increase to 80 mg/day if symptoms fail to improve after 4 weeks AND the initial dose is well tolerated 1
  • Strong CYP2D6 inhibitors include paroxetine, fluoxetine, and quinidine 1

For Hepatic Impairment

  • Moderate hepatic impairment (Child-Pugh Class B): Reduce initial and target doses to 50% of normal (start at 20 mg, target 40 mg) 1
  • Severe hepatic impairment (Child-Pugh Class C): Reduce initial and target doses to 25% of normal (start at 10 mg, target 20 mg) 1

Administration Details

  • May be taken with or without food 1
  • Capsules must be swallowed whole, not opened 1
  • Can be discontinued without tapering 1

Critical Safety Monitoring

  • Screen for bipolar disorder (personal or family history of bipolar disorder, mania, or hypomania) before initiating treatment 1
  • Monitor closely for suicidality, clinical worsening, and unusual behavior changes, especially during the first few months or at dose changes 2
  • Watch for behavioral activation/agitation (motor or mental restlessness, insomnia, impulsiveness, aggression) early in treatment or with dose increases 2

Common Adverse Effects to Anticipate

  • Dry mouth, insomnia, nausea, decreased appetite, constipation, dizziness, sweating, dysuria, sexual problems, and palpitations occur more frequently than with placebo 3, 4
  • Gastrointestinal effects (nausea, vomiting, abdominal pain) and decreased appetite are common 2
  • Modest increases in heart rate (1-2 beats per minute) and blood pressure (1-4 mm Hg) are typical 5

Key Clinical Pitfalls to Avoid

  • Do not increase dose too rapidly - behavioral activation and agitation are more likely with rapid escalation 2
  • Do not expect immediate results - unlike stimulants, atomoxetine requires 6-12 weeks for full effect 2
  • Do not forget CYP2D6 status - poor metabolizers have 10-fold higher plasma concentrations and require slower titration 6
  • Do not skip hepatic function assessment - dose adjustments are essential in hepatic impairment 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.